BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-860@pharmaconomics
DTSTAMP:20260707T025314Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:ANTX Phase 2 — epetraborole (estimated date)
DESCRIPTION:Phase 2 trial results for epetraborole in M. abscessus complex lung disease are due ~ Jun 30\, 2027. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1880438/000119312526110681/antx-ex99_1.htm\n\nTrack it: https://pharmaconomics.com/e/860
URL:https://pharmaconomics.com/e/860
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:ANTX catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR